<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xinyuan Lai</style></author><author><style face="normal" font="default" size="100%">Hui Zhuang</style></author><author><style face="normal" font="default" size="100%">Li, Tong</style></author><author><style face="normal" font="default" size="100%">Kuanhui Xiang</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Protocol for characterizing the inhibition of SARS-CoV-2 infection by a protein of interest in cultured cells</style></title><secondary-title><style face="normal" font="default" size="100%">STAR Protocols</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.sciencedirect.com/science/article/pii/S2666166722006827</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Here, we present a protocol to characterize the antiviral ability of a protein of interest to SARS-CoV-2 infection in cultured cells, using MUC1 as an example. We use SARS-CoV-2 ΔN trVLP system, which utilizes transcription and replication-competent SARS-CoV-2 virus-like particles lacking nucleocapsid gene. We describe the optimized procedure to analyze protein interference of viral attachment and entry into cells, and RT-qPCR-based quantification of viral infection. The protocol can be applied to characterize more antiviral candidates and clarify their functioning stage.</style></abstract></record></records></xml>